Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma

Summary

This pilot early phase I trial studies the side effects and how well imiquimod and pembrolizumab work in treating patients with stage IIIB-IV melanoma. Imiquimod may stimulate the immune system. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving imiquimod and pembrolizumab may work better at treating melanoma.

Timeline

Start

2017-12-20

Primary completion

2019-10-15

Completion

2019-10-15

Drugs

Indications